Testing faricimab for a rare eye disease linked to histoplasmosis
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a drug called faricimab (brand name Vabysmo) for treating abnormal blood vessel growth in the back of the eye, caused by a past infection with histoplasmosis. The goal is to see if it helps improve vision over 52 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and willing to follow all study procedures for a year.
- You have a specific type of eye damage (abnormal blood vessels) from a prior histoplasmosis infection, confirmed by eye exam and imaging.
- Your best corrected vision in the study eye is between 20/40 and 20/400 (moderate to severe vision loss).
- The center of your retina (macula) is thicker than 300 microns on an OCT scan.
- You have not had anti-VEGF injections in the study eye in the last 6 months.
- You do not have other major eye diseases or conditions in the study eye that could affect the results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
This trial tests a drug called faricimab for a type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). It aims to see if the drug is safe, works well, and how long the effects last in patients who have not been treated before.
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
This trial tests whether faricimab (a medicine injected into the eye) can help reduce fluid buildup in patients with chronic central serous chorioretinopathy (CSCR). It compares the drug to a sham injection to see if it improves vision and reduces fluid.
Hear when a new Presumed Ocular Histoplasmosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.